 |
|
K-State professor developing new strategies for delivery of drugs to fight, treat tuberculosis
August 31, 2005MANHATTAN, KAN. - It has been identified by the World Health Organization as the most dangerous infectious disease, causing more deaths - more than 2 million a year - than any other single infection. Approximately one-third of the world's population is already infected.
"It" is Mycobacterium tuberculosis.
A Kansas State University chemistry professor is seeking to stem the tide in the war against TB. According to the WHO, no new antituberculosis drugs have been marketed during the last 30 years. As such, new strategies are needed to lead to the successful development of antituberculosis therapies.
K-State's Stefan H. Bossmann is researching a new strategy for treatment of the deadly infectious disease using ruthenium-polypyridyl-complexes as antimycobacterial drugs.
Bossmann's research explores unique physical and chemical properties of channel proteins called porins, isolated from Mycobacterium smegmatis and Mycobacterium tuberculosis. He is attempting to understand the working principles of porin channels in natural and artificial environments and he hopes to eventually develop supramolecular model systems to serve as physical models for the biological function of the porin systems.
Bossmann will discuss his research at the American Chemical Society's national meeting and exposition, Aug. 28-Sept. 1, in Washington, D.C. He will give an oral presentation at the conference Tuesday, Aug. 30.
"We have more and more resistant strains developing in Asia and Russia. We're also getting a large number of patients infected with TB immigrating to the United States," Bossmann said.
According to Bossmann, not many antibiotics actually work in treating TB because the disease has been steadily developing resistance to them. This makes new strategies for the delivery of drugs urgently needed, he said.
"It will become extremely difficult to treat cases of TB, in say 10 to 20 years down the road, because new treatment possibilities have not been developed," he said.
A "cocktail" consisting of a variety of drugs must be used to treat TB patients and they must be treated for several months, Bossmann said, but the problem with the conventional treatment is that microbacteria in TB grows slowly, helping it to evade the drugs.
"You might think this is a disadvantage, but it is not," Bossmann said. "The microbacteria has the talent to evade all of those medicines."
Mycobacterium TB has just a few pores in its outer walls which regulate basically all of its metabolics, Bossmann said. When the mycobacteria senses something dangerous like antibiotics, it simply closes the channel.
Bossmann's research is targeting the channels.
"It is the only way for the cells to have an exchange with the outside world as far as we know: to block them and put complexes in which bond irreversibly within those channels, depriving the channels of any possibility to take nutrients in or to discharge waste from its metabolism," he said. "This approach can permanently deactivate TB so that the human immune system can deal with it."
Kansas State University
K-State's Stefan H. Bossmann is researching a new strategy for treatment of the deadly infectious disease using ruthenium-polypyridyl-complexes as antimycobacterial drugs.
Bossmann's research explores unique physical and chemical properties of channel proteins called porins, isolated from Mycobacterium smegmatis and Mycobacterium tuberculosis. He is attempting to understand the working principles of porin channels in natural and artificial environments and he hopes to eventually develop supramolecular model systems to serve as physical models for the biological function of the porin systems.
Bossmann will discuss his research at the American Chemical Society's national meeting and exposition, Aug. 28-Sept. 1, in Washington, D.C. He will give an oral presentation at the conference Tuesday, Aug. 30.
"We have more and more resistant strains developing in Asia and Russia. We're also getting a large number of patients infected with TB immigrating to the United States," Bossmann said.
According to Bossmann, not many antibiotics actually work in treating TB because the disease has been steadily developing resistance to them. This makes new strategies for the delivery of drugs urgently needed, he said.
"It will become extremely difficult to treat cases of TB, in say 10 to 20 years down the road, because new treatment possibilities have not been developed," he said.
A "cocktail" consisting of a variety of drugs must be used to treat TB patients and they must be treated for several months, Bossmann said, but the problem with the conventional treatment is that microbacteria in TB grows slowly, helping it to evade the drugs.
"You might think this is a disadvantage, but it is not," Bossmann said. "The microbacteria has the talent to evade all of those medicines."
Mycobacterium TB has just a few pores in its outer walls which regulate basically all of its metabolics, Bossmann said. When the mycobacteria senses something dangerous like antibiotics, it simply closes the channel.
Bossmann's research is targeting the channels.
"It is the only way for the cells to have an exchange with the outside world as far as we know: to block them and put complexes in which bond irreversibly within those channels, depriving the channels of any possibility to take nutrients in or to discharge waste from its metabolism," he said. "This approach can permanently deactivate TB so that the human immune system can deal with it."
Kansas State University
Tuberculosis Current Events and Tuberculosis News RSSDisease diagnosis in just 15 minutes
Testing for diseases such as cancer and multiple sclerosis could soon be as simple as using a pregnancy testing kit.
New way to make malaria medicine also first step in finding new antibiotics
University of Illinois microbiology professor William Metcalf and his collaborators have developed a way to mass-produce an antimalarial compound, potentially making the treatment of malaria less expensive.
How to differentiate abdominal tuberculosis from lymphomas?
The incidence of tuberculosis is increasing. Lymphadenopathy is the most common manifestation of abdominal tuberculosis and may, in up to 55% of cases without other evidence of abdominal involvement, be easily confused with lymphomas involving abdominal lymph nodes.
New insights could lead to a better pneumococcal vaccine
Discovery of a new, previously unknown mechanism of immunity suggests that there may be a better way to protect vulnerable children and adults against Streptococcus pneumoniae (pneumococcal) infection, say researchers at Children's Hospital Boston and Harvard School of Public Health (HSPH).
Tuberculosis drug shows promise against latent bacteria
A new study has shown that an investigational drug (R207910, currently in clinical trials against multi-drug resistant tuberculosis strains) is quite effective at killing latent bacteria. This revelation suggests that R207910 may lead to improved and shortened treatments for this globally prevalent disease.
Novel tuberculosis vaccine in Germany in clinical phase
For the first time in more than 80 years a promising live vaccine against tuberculosis has passed into the clinical phase in Germany: Since Monday of this week the new vaccine, which goes by the designation "VPM1002", has begun safety testing on volunteers in a Phase I clinical trial in Neuss, Germany.
New method to overcome multiple drug resistant diseases developed by Stanford researchers
Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them.
India continues to progress in AIDS vaccine development efforts
A second Phase I AIDS vaccine clinical trial in India was successfully completed, the Indian Council of Medical Research, the National AIDS Control Organization and the International AIDS Vaccine Initiative announced. The results of the trial of an MVA-based AIDS vaccine candidate (TBC-M4), which was conducted in Chennai, indicated that the vaccine candidate had acceptable levels of safety and was well tolerated.
Extensively drug-resistant tuberculosis found in California
In the first statewide study of extensively drug-resistant tuberculosis (XDR TB) in the United States, California officials have identified 18 cases of the dangerous and difficult-to-treat disease between 1993 and 2006, and 77 cases that were one step away from XDR TB. The study appears in the August 15 issue of Clinical Infectious Diseases, now available online.
Comprehensive treatment of extensively drug-resistant TB works, study finds
The death sentence that too often accompanies a diagnosis of extensively drug-resistant tuberculosis (XDR-TB) can be commuted if an individualized outpatient therapy program is followed - even in countries with limited resources and a heavy burden of TB.
More Tuberculosis Current Events and Tuberculosis News Articles
 | The Bioarchaeology of Tuberculosis: A Global View on a Reemerging Disease by CHARLOTTE ROBERTS, JANE BUIKSTRA Though apparently in decline during the first half of the 20th century, tuberculosis has reawakened in both developed and developing countries, particularly among susceptible populations with immunodeficiency disorders.... |
 | Tuberculosis and the Politics of Exclusion: A History of Public Health and Migration to Los Angeles (Critical Issues in Health and Medicine) by Emily K. Abel Though notorious for its polluted air today, the city of Los Angeles once touted itself as a health resort. After the arrival of the transcontinental railroad in 1876, publicists launched a campaign to portray the city as the promised land, circulating countless stories of miraculous cures for the sick and debilitated. As more and more migrants poured in, however, a gap emerged between... |
 | The White Plague: Tuberculosis, Man, and Society by Rene J. Dubos |
 | Living in the Shadow of Death: Tuberculosis and the Social Experience of Illness in American History by Sheila M. Rothman Tuberculosis -- once the cause of as many as one in five deaths in the U.S. -- crossed all boundaries of class and gender, but the methods of treatment for men and women differed radically. While men were encouraged to go out to sea or to the open country, women were expected to stay at home, surrounded by family, to anticipate a lingering death. Several women, however, chose rather to head for... |
 | Captain of Death: The Story of Tuberculosis by Thomas M. Daniel The dramatic story of tuberculosis is told here in a straightforward and accessible style. It presents the stories of persons connected with the disease, either as victims, or as those who made contributions to our knowledge of it; in addition to these personal accounts, the book unfolds the history and explains the pathogenesis of TB. The re-emergence of tuberculosis as a major American public... |
 | Consumed in the City: Observing Tuberculosis at Century's End by Paul Joseph Draus As a public health field worker assigned to control tuberculosis in New York and Chicago in the 1990s, Paul Draus encountered the horrible effects of tuberculosis resurgence in urban areas, and the intersections of disease, blight, and poverty. Consumed in the City grows out of his experiences and offers a persuasive case for thinking about—and treating—tuberculosis as an inseparable... |
 | Tuberculosis Pearls by Neil W. Schluger, Timothy J., M.D. Harkin New York University, New York City. Handbook of 75 clinical case presentations in tuberculosis, with diagnosis, one-page discussion, and pearls. For residents and medical students. Halftone illustrations. DNLM: Tuberculosis, Pulmonary - diagnosis - case... |
 | The Making of a Social Disease: Tuberculosis in Nineteenth-Century France by David S. Barnes In this first English-language study of popular and scientific responses to tuberculosis in nineteenth-century France, David Barnes provides a much-needed historical perspective on a disease that is making an alarming comeback in the United States and Europe. Barnes argues that French perceptions of the disease--ranging from the early romantic image of a consumptive woman to the later view of a... |
 | Clinical Tuberculosis (A Hodder Arnold Publication) by Peter D Davies, Peeter Barnes, Stephen B Gordon Clinical Tuberculosis remains an indispensable resource for respiratory physicians, infectious disease specialists, public health workers and other individuals involved in the management and control of tuberculosis worldwide. This established reference is a comprehensive accoutn of tuberculosis, providing up-to-date and authoritative information on all aspects of the disease. It gives practical... |
 | Contagion and Confinement: Controlling Tuberculosis along the Skid Road by Barron H. Lerner Most historians of tuberculosis have focused on the sanatorium era of the early twentieth century, losing interest in the disease with the discovery of curative antibiotics in the 1940s. In Contagion and Confinement, Barron H. Lerner offers the first in-depth look at the history of tuberculosis control in the antibiotic era, providing a vital account of this neglected chapter in the history of... |
| © 2008 BrightSurf.com |